Meta-analysis finds Cytoflavin may aid recovery after ischemic stroke

A pooled analysis of nine studies suggests that Cytoflavin, a metabolic and antioxidant drug combination, may improve neurological and functional recovery in people hospitalized with acute ischemic stroke, though the evidence carries substantial caveats. The work, a systematic review and meta-analysis led by researchers at the Faculty of Medicine, Diponegoro University in Semarang, Indonesia, was registered prospectively and analyzed data from 3,254 participants counted across treatment arms. Because several trials compared two Cytoflavin doses against a single shared control group, and because the same patients were measured at multiple time points, the number of unique participants behind each pooled result was smaller, reaching 1,379 for the primary neurological outcome.

Acute ischemic stroke remains a leading cause of long-term disability worldwide. Reperfusion therapies such as thrombolysis and thrombectomy can restore blood flow, but they do not fully prevent the cascade of secondary brain injury that follows, which is why researchers continue to search for adjunctive neuroprotective agents. Cytoflavin, a compound combining metabolic and antioxidant activity, has been proposed as one such candidate, but its clinical efficacy had remained underexplored until now.

The review focused on four domains of recovery. The first was neurological status, measured with the National Institutes of Health Stroke Scale, a clinical scoring tool in which lower numbers indicate less impairment. Across the pooled studies, Cytoflavin was associated with a mean reduction of 2.63 points on this scale compared with control, with a 95 percent confidence interval of 3.15 to 2.10 points. Because the interval excludes zero, the authors graded this finding as moderate certainty, though the magnitude of the benefit and its clinical meaning remain open to interpretation given the diversity of the underlying trials.

Functional independence, assessed with the Barthel Index, showed the largest absolute effect. Patients receiving Cytoflavin scored on average 19.29 points higher than controls, with a confidence interval of 9.52 to 29.07 points, also rated moderate certainty. As with the neurological score, however, this estimate rests on studies with considerable clinical and methodological differences.

Cognitive performance, measured with the Mini-Mental State Examination, and disability ratings on the modified Rankin Scale showed smaller and less certain effects. The pooled cognitive benefit was 6.93 points, with a confidence interval of 1.39 to 12.47, and the Rankin Scale difference was 0.41 points, with an interval of 0.74 to 0.09. Both were graded low certainty. The authors also flagged a technical problem with the Rankin result: the scale is inherently ordinal, with categories that are not evenly spaced, yet the analysis treated continuous summary statistics as if they were interval data. That statistical choice limits how the result should be read.

Infarct volume, the physical size of the damaged brain region, told a more complicated story. The effects diverged by evaluation time point. At day ten, one study reported a marginal increase in lesion volume of 0.17 cubic centimeters. At day twenty-one, the pooled estimate pointed to a non-significant reduction of 4.73 cubic centimeters, with a confidence interval of 11.41 to 1.95, graded very low certainty.

Statistical heterogeneity was a persistent theme. The I-squared statistic, which quantifies the share of variation in results attributable to differences between studies rather than chance, ranged from 0 to 100 percent across outcomes. Notably, this variation persisted even after the researchers applied a unit-of-analysis correction, in which a shared control group compared against two separate Cytoflavin dose arms was split proportionally between the two comparisons to avoid double-counting the same participants. The persistence of high heterogeneity after this correction indicates genuine clinical and methodological diversity among the included studies, not merely a counting artifact.

Methodological quality was assessed with the Cochrane Risk of Bias tool and the Newcastle-Ottawa Scale, standard instruments for randomized and observational studies respectively. The authors concluded that heterogeneity and methodological limitations temper the promise of the findings.

What does this mean for practice? The evidence base is too heterogeneous and too limited in certainty for the analysis to settle the question of whether Cytoflavin should become routine adjunctive therapy. The moderate-certainty results for neurological and functional scores are encouraging signals, and the low-certainty cognitive and disability findings point in the same direction, but the imaging results are equivocal and the ordinal-scale issue adds a further caution. The authors themselves call for further large-scale, high-quality studies to confirm efficacy and to optimize treatment protocols, including dose and timing, before any change in stroke care could be justified.

For now, the analysis stands as a map of what is known and unknown about a candidate neuroprotective agent. It quantifies the potential size of the benefit across four clinically relevant outcomes, exposes where the evidence is weakest, and defines the parameters that future trials must address.

Subject of Research: The efficacy of the metabolic and antioxidant compound Cytoflavin as a neuroprotective adjunct therapy in acute ischemic stroke, evaluated through a systematic review and meta-analysis.

Article Title: Cytoflavin's neuroprotective effect in acute ischemic stroke: a systematic review and meta-analysis

Article References: Retnaningsih, R., Tugasworo, D., Arinta Puspita, W., Elvika, C., & Pratama, A. A. (2026). Cytoflavin's neuroprotective effect in acute ischemic stroke: a systematic review and meta-analysis. Frontiers in Stroke, 5, Article 1775376. https://doi.org/10.3389/fstro.2026.1775376

Image Credits: AI Generated

DOI: 10.3389/fstro.2026.1775376

Keywords: Cytoflavin, acute ischemic stroke, systematic review, meta-analysis, neuroprotection, NIHSS, Barthel Index, MMSE, infarct volume, antioxidant therapy, stroke recovery, heterogeneity